La Puente, California Clinical Trials

A listing of La Puente, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

hras gene
recurrent thyroid gland carcinoma
donor lymphocyte infusion
HRAS
nitrosoureas
City of Hope Comprehensive Cancer Center
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

metastatic malignant solid tumor
kras
kras g12c mutation
solid tumor
solid tumour
City of Hope Comprehensive Cancer Center
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

lymphoma
cutaneous t-cell lymphoma
cancer therapy
hair thinning
measurable disease
Investigational Site Number 8400001
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +4 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

autologous hematopoietic stem cell transplant
immunotherapeutic agent
thalidomide
daratumumab
bortezomib
Investigational Site Number 8400002
 (9.5 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +7 other locations
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.

renal cell carcinoma
karnofsky performance status
carcinoma
Research Site 2
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

This phase III trial studies how well a telehealth self-management program works in improving survivorship care and outcomes in stage I-III non-small cell lung cancer or colorectal cancer survivors. Survivor self-management program focuses on coaching patients on follow-up care after cancer treatments. Participating in the program may improve knowledge and …

stage ib lung cancer ajcc v8
stage iiib lung cancer ajcc v8
stage ii colorectal cancer ajcc v8
stage ia1 lung cancer ajcc v8
colorectal cancer
City of Hope Medical Center
 (8.4 away) Contact site
  • 4 views
  • 19 Feb, 2024
  • 1 location
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

combination therapy
testosterone
antiandrogens
antiandrogen therapy
taxane
The Oncology Institute of Hope & Innovation
 (5.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
Follow-up Study of Growth Safety and Efficacy of an Infant Formula for Healthy Term Infants

The purpose of this two-month follow-up study is to continue to follow growth, safety, and other health outcomes of infants fed a new infant formula for term infants or comparator formula. A reference group of human milk-fed infants will also be followed. This study is designed in accordance with Good …

San Gabriel Women's Health
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +24 other locations
Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema

This trial studies how well the Remotivation Process in an occupational therapy program works in improving adherence to lymphedema treatment programs in patients with breast cancer-related lymphedema. Lymphedema treatment programs are well developed and effective, but adherence to these programs are an issue. The Remotivation Process is a series of …

breast carcinoma
lymphedema
cancer
breast cancer
carcinoma
City of Hope Medical Center
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.

combination therapy
PCR test
fluoropyrimidine
colorectal cancer
solid tumour
City of Hope
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations